Sexual Dysfunction in Hypertensive Women (DYSFHO)

Toulouse University Hospital

Status

Enrolling

Conditions

Hypertension

Treatments

Behavioral: Morisky Questionaire

Behavioral: Questionnaire on sexual activity

Behavioral: Scale on hospital anxiety and depression

Biological: Blood sample for the determination of antihypertensives or their metabolites.

Study type

Interventional

Funder types

Other

Identifiers

NCT05156385

RC31/19/0553

Details and patient eligibility

About

Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia.

Hypertension is a contributing factor, and nonadherence to medication could amplify it.

There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments.

The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers.

The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.

Enrollment

348 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women over 18,
Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine,
Having signed the informed consent form.
Beneficiary or affiliated to a French Social insurance

Exclusion criteria

Patients with bariatric surgery,
Patients under guardianship/trusteeship/protection of justice,
Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.